<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938651</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BRE 1277</org_study_id>
    <secondary_id>NCI-2013-00435</secondary_id>
    <nct_id>NCT01938651</nct_id>
  </id_info>
  <brief_title>Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer</brief_title>
  <official_title>Ultra-High Field (7 Tesla) MRI/MRS Evaluation of Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot clinical trial studies ultra-high field magnetic resonance imaging (MRI) and&#xD;
      magnetic resonance spectroscopy (MRS) techniques in diagnosing breast cancer. New diagnostic&#xD;
      procedures may be a more sensitive way to detect breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To implement quantitative dynamic contrast-enhanced (DCE)-MRI, diffusion-weighted&#xD;
      (DW)-MRI, 31 phosphorus (31P) MRS, magnetization transfer (MT)-MRI, chemical exchange&#xD;
      saturation transfer (CEST)-MRI, and high-resolution structural imaging at 7 Tesla in patients&#xD;
      for diagnosing breast tumors.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor&#xD;
      cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using&#xD;
      MT-MRI, and cellular protein content using CEST-MRI. Diagnostic performance of one, or a&#xD;
      combination, of these metrics will be investigated in the context of breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    funding ceased&#xD;
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and specificity</measure>
    <time_frame>At time of imaging procedure</time_frame>
    <description>Ninety-percent simultaneous confidence rectangles for sensitivity and specificity will be constructed at the 25th, 50th (median), and 75th percentiles of the model predicted probability of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological disease status</measure>
    <time_frame>At time of imaging procedure</time_frame>
    <description>A generalized linear mixed models analysis of variance with a logit link will be used to predict pathological disease status from MRI and MRS parameters.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (7T ultra high-field MRI/MRS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using MT-MRI, and cellular protein content using CEST-MRI. All of these procedures are integrated into a single MRI exam lasting under 60 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>high field strength magnetic resonance imaging</intervention_name>
    <description>Undergo 7T MRI</description>
    <arm_group_label>Diagnostic (7T ultra high-field MRI/MRS)</arm_group_label>
    <other_name>high field strength MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance spectroscopic imaging</intervention_name>
    <description>Undergo 31P MRS</description>
    <arm_group_label>Diagnostic (7T ultra high-field MRI/MRS)</arm_group_label>
    <other_name>1H-nuclear magnetic resonance spectroscopic imaging</other_name>
    <other_name>Proton Magnetic Resonance Spectroscopic Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemical exchange saturation transfer magnetic resonance imaging</intervention_name>
    <description>Undergo CEST-MRI</description>
    <arm_group_label>Diagnostic (7T ultra high-field MRI/MRS)</arm_group_label>
    <other_name>CEST MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>diffusion-weighted magnetic resonance imaging</intervention_name>
    <description>Undergo DW-MRI</description>
    <arm_group_label>Diagnostic (7T ultra high-field MRI/MRS)</arm_group_label>
    <other_name>diffusion-weighted MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dynamic contrast-enhanced magnetic resonance imaging</intervention_name>
    <description>Undergo DCE-MRI</description>
    <arm_group_label>Diagnostic (7T ultra high-field MRI/MRS)</arm_group_label>
    <other_name>DCE-MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must have signed an approved consent form&#xD;
&#xD;
          -  Must be at least 18 years old&#xD;
&#xD;
          -  Subjects must have undergone x-ray mammography and/or ultrasonography&#xD;
&#xD;
          -  Subjects must have undergone standard clinical (1.5 Tesla) MRI as part of their&#xD;
             standard-of-care diagnostic workup:&#xD;
&#xD;
               -  To evaluate the extent of disease for a previously diagnosed cancer, or&#xD;
&#xD;
               -  To evaluate a clinically suspected lesion that was occult on mammography and/or&#xD;
                  ultrasonography, or&#xD;
&#xD;
               -  Because the patient is considered high-risk (according to National Comprehensive&#xD;
                  Cancer Network [NCCN] criteria)&#xD;
&#xD;
          -  Subjects must be classified Breast Imaging-Reporting and Data System (BI-RADS) 4 or 5&#xD;
&#xD;
          -  Subjects must be scheduled for diagnostic biopsy to evaluate a lesion that measures&#xD;
             &gt;10 mm in the greatest dimension.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who have distant metastases&#xD;
&#xD;
          -  Subjects who have any type of bioimplant activated by mechanical, electronic, or&#xD;
             magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators,&#xD;
             electronic infusion pumps, aneurysm clip, etc), because such devices may be displaced&#xD;
             or malfunction&#xD;
&#xD;
          -  Subjects who have any type of ferromagnetic bioimplant that could potentially be&#xD;
             displaced by the magnetic field of the MRI scanner&#xD;
&#xD;
          -  Subjects who may have shrapnel imbedded in their bodies (such as from war wounds),&#xD;
             metal workers, and machinists (potential for metallic fragments in or near the eyes)&#xD;
&#xD;
          -  Subjects with a history of renal disease (including renal cancer), diabetes, or human&#xD;
             immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Creatinine &gt;= 1.5 times upper limit of normal&#xD;
&#xD;
          -  Estimated glomerular filtration rate &lt; 30 mL/min&#xD;
&#xD;
          -  Subjects who are pregnant or breast-feeding; the MRI Procedure Screening Form will be&#xD;
             used to identify and exclude subjects who are pregnant or breastfeeding; a urine&#xD;
             pregnancy test/or serum human chorionic gonadotropin (HCG) will also be performed for&#xD;
             pre-menopausal women who are not using contraceptives&#xD;
&#xD;
          -  Subjects who have exhibited past allergic or other adverse reactions in response to&#xD;
             intravenous injection of Magnevist (gadopentetate dimeglumine) or other&#xD;
             gadolinium-containing contrast agents&#xD;
&#xD;
          -  Subjects who exhibit noticeable anxiety and/or claustrophobia or who exhibit severe&#xD;
             vertigo when they are moved into the magnet bore&#xD;
&#xD;
          -  Subjects incapable of giving informed written consent, for the following reasons:&#xD;
&#xD;
               -  Inability to adhere to the experimental protocols for any reason&#xD;
&#xD;
               -  Inability to communicate with the research team&#xD;
&#xD;
               -  Limited ability to give informed consent due to mental disability, altered mental&#xD;
                  status, confusion, or psychiatric disorders&#xD;
&#xD;
               -  Prisoners or other individuals deemed to be susceptible to coercion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Yankeelov</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vicc.org/ct/</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>August 2, 2016</last_update_submitted>
  <last_update_submitted_qc>August 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Thomas Yankeelov</investigator_full_name>
    <investigator_title>Director of Cancer Imaging Research, Vanderbilt University Institute of Imaging Science (VUIIS); Associate Professor of Radiology and Radiological Sciences, Biomedical Engineering, Physics and Astronomy, and Cancer Biology;</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

